To ask the Secretary of State for Exiting the European Union, what discussions he has had with pharmaceutical companies on potential employment in that sector for qualified persons for pharmacovigilance, marketing authorisation holders and qualified people for batch release after the UK leaves the EU.
Stakeholder engagement is a central element of our plan to build a national consensus around our negotiating position. We are listening and talking to as many pharmaceuticals organisations, companies and institutions as possible.
The recent Goods position paper outlines our ambitions for a deep and special partnership which allows the freest and most frictionless possible trade in goods. In the context of withdrawal, the paper is clear that we want to reach an agreement that minimises disruption for businesses and consumers, including by agreeing the continued validity of existing market authorisations and compliance activity in regard to the pharmaceuticals sector.